Rodman & Renshaw Highlights (Z)-Endoxifen Potential as It Initiates Buy on Atossa Therapeutics
Rodman & Renshaw assigns Buy rating and $12 PT on (Z)-endoxifen, highlighting breast cancer program and rare disease upside.
/ 2 items
Rodman & Renshaw assigns Buy rating and $12 PT on (Z)-endoxifen, highlighting breast cancer program and rare disease upside.
Atossa Therapeutics receives FDA orphan drug designation for (Z)-endoxifen to treat Duchenne muscular dystrophy, a rare genetic muscle-wasting disease.